25.65
Schlusskurs vom Vortag:
$26.13
Offen:
$25.98
24-Stunden-Volumen:
1.97M
Relative Volume:
0.48
Marktkapitalisierung:
$3.29B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-99.15M
KGV:
-27.58
EPS:
-0.93
Netto-Cashflow:
$-74.25M
1W Leistung:
-11.40%
1M Leistung:
-10.53%
6M Leistung:
-58.38%
1J Leistung:
-68.72%
Viking Therapeutics Inc Stock (VKTX) Company Profile
Firmenname
Viking Therapeutics Inc
Sektor
Branche
Telefon
858-704-4660
Adresse
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Vergleichen Sie VKTX mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
VKTX
Viking Therapeutics Inc
|
25.65 | 3.29B | 0 | -99.15M | -74.25M | -0.93 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-02-13 | Eingeleitet | Scotiabank | Sector Outperform |
2025-02-07 | Eingeleitet | Citigroup | Neutral |
2024-12-02 | Eingeleitet | Piper Sandler | Overweight |
2024-11-22 | Eingeleitet | B. Riley Securities | Buy |
2024-11-04 | Bestätigt | H.C. Wainwright | Buy |
2024-09-11 | Eingeleitet | JP Morgan | Overweight |
2024-06-27 | Eingeleitet | Morgan Stanley | Overweight |
2024-05-16 | Hochstufung | Raymond James | Outperform → Strong Buy |
2024-03-26 | Bestätigt | Oppenheimer | Outperform |
2024-03-07 | Eingeleitet | Jefferies | Buy |
2024-02-28 | Bestätigt | Oppenheimer | Outperform |
2023-05-31 | Fortgesetzt | ROTH MKM | Buy |
2023-03-28 | Bestätigt | Maxim Group | Buy |
2023-03-17 | Eingeleitet | Stifel | Buy |
2021-07-29 | Fortgesetzt | BTIG Research | Buy |
2021-05-25 | Herabstufung | Raymond James | Strong Buy → Outperform |
2020-06-05 | Eingeleitet | BMO Capital Markets | Outperform |
2020-05-05 | Eingeleitet | Chardan Capital Markets | Buy |
2020-05-01 | Eingeleitet | BTIG Research | Buy |
2019-07-16 | Eingeleitet | Oppenheimer | Outperform |
2019-06-25 | Eingeleitet | Stifel | Buy |
2019-03-29 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
2019-03-14 | Bestätigt | Maxim Group | Buy |
2019-02-22 | Eingeleitet | SVB Leerink | Mkt Perform |
2018-12-12 | Eingeleitet | B. Riley FBR | Buy |
2018-11-19 | Hochstufung | Raymond James | Outperform → Strong Buy |
2018-09-18 | Bestätigt | H.C. Wainwright | Buy |
2018-09-18 | Bestätigt | Maxim Group | Buy |
2018-09-18 | Bestätigt | Raymond James | Outperform |
2018-07-20 | Eingeleitet | SunTrust | Buy |
2018-06-28 | Eingeleitet | Raymond James | Outperform |
2018-06-01 | Bestätigt | Laidlaw | Buy |
2018-05-31 | Bestätigt | Maxim Group | Buy |
2018-03-26 | Fortgesetzt | H.C. Wainwright | Buy |
2017-11-28 | Bestätigt | Maxim Group | Buy |
2017-11-21 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Viking Therapeutics Inc Aktie (VKTX) Neueste Nachrichten
A Closer Look at Viking Therapeutics's Options Market Dynamics - Benzinga
Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet - Yahoo Finance
VKTX Finishes Enrolment in Mid-Stage Study on Oral Weight-Loss Drug - Yahoo Finance
Viking Therapeutics Skids Despite 'Rapid' Enrollment In Obesity Pill Study - Investor's Business Daily
Health Care Down as Viking Slides -- Health Care Roundup - Marketscreener.com
Viking Therapeutics Completes Enrollment for Phase 2 Trial of Oral Obesity Tablet - Patient Care Online
Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity - Marketscreener.com
Major Milestone: Viking's Oral Weight Loss Drug Advances with 280-Patient Phase 2 Trial - StockTitan
Better Stock to Buy Right Now: Viking Therapeutics vs. Eli Lilly - MSN
Viking Therapeutics, Inc. (VKTX) Rises But Trails Market: What Investors Should Know - MSN
(VKTX) Investment Analysis - Stock Traders Daily
Market Whales and Their Recent Bets on VKTX Options - Benzinga
1 Biotech Stock Down 52% That Could Soar by 233%, According to Wall Street - Yahoo Finance
Down 65% From Its 52-Week High, Is Viking Therapeutics Stock a Bargain Buy? - Yahoo
Why Novo Nordisk Stock Outpaced the Market on Tuesday - The Motley Fool
Is Viking Therapeutics the Next Blockbuster GLP-1 Stock? - MarketBeat
Viking Therapeutics (NasdaqCM:VKTX) Soars 10% With CordenPharma Manufacturing Agreement - Yahoo Finance
Viking Therapeutics Starts Mid-Stage Study on Oral Weight-Loss Drug - MSN
Viking Therapeutics Just Inked A $150 Million Manufacturing Deal. Here's Why Shares Crumbled. - MSN
Health Care Down as Traders Seek Out Defensive Sectors -- Health Care Roundup -March 14, 2025 at 05:24 pm EDT - Marketscreener.com
Why Viking Therapeutics Inc. (VKTX) Is Skyrocketing Today? - MSN
Viking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some Facts to Note - MSN
Viking Therapeutics: No Buyout Needed Now (NASDAQ:VKTX) - Seeking Alpha
(VKTX) Long Term Investment Analysis - Stock Traders Daily
How to Play VKTX Stock Amid Manufacturing Deal With CordenPharma - Zacks Investment Research
Viking Therapeutics (NASDAQ:VKTX) Earns “Buy” Rating from HC Wainwright - Defense World
10 Stocks Skyrocketing Today - Insider Monkey
Why VKTX Stock is Moving Today - GuruFocus.com
Viking Therapeutics Secures Manufacturing Agreement with CordenPharma, Boosting Growth Prospects and Investor Appeal - TipRanks
Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped - Yahoo
Viking Therapeutics’ new contract is a game changer. Here’s how much money it could bring in. - MarketWatch
Behind the Scenes of Viking Therapeutics's Latest Options Trends - Benzinga
B. Riley sees two key positives in Viking manufacturing agreement - Yahoo Finance
Viking Therapeutics call volume above normal and directionally bullish - TipRanks
Viking shares slip after manufacturing deal announced - The Pharma Letter
VKTX Inks Manufacturing Deal With CordenPharma for Obesity Drug Supply - Yahoo Finance
Viking Therapeutics Is Ready For A Standalone Future (NASDAQ:VKTX) - Seeking Alpha
Viking Therapeutics Secures Strategic Manufacturing Agreement with CordenPharma, Boosting Growth Potential and Earning Buy Rating - TipRanks
Viking Therapeutics Secures Strategic Manufacturing Agreement, Boosting Investor Confidence and Phase 3 Trial Prospects - TipRanks
Bank of New York Mellon Corp Grows Position in Viking Therapeutics, Inc. (NASDAQ:VKTX) - Defense World
CordenPharma and Viking Therapeutics Sign Long-Term Strategic Partnership for Integrated Supply of GLP-1 Peptides, Injectables and Oral Formulations - Barchart
Health Care Down on Flight From Biotech, Obesity Drug Makers -- Health Care Roundup - Marketscreener.com
Viking Therapeutics Signs Broad Manufacturing Agreement With CordenPharma to Support Commercialization of VK2735 - The Malaysian Reserve
Viking Therapeutics: Finally, Here Comes The Buying Opportunity (Upgrade) - Seeking Alpha
Stellantis, Tesla, Viking Therapeutics: Market Minute - Yahoo Finance
Viking Therapeutics closer to bringing its Ozempic competitor to market - Yahoo Finance
Viking Therapeutics Shares Fall After Manufacturing Deal With CordenPharma -March 11, 2025 at 11:08 am EDT - Marketscreener.com
Wall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy? - MSN
Strategic Manufacturing Deal Boosts Viking Therapeutics’ Stock Outlook - TipRanks
Viking Therapeutics Signs Broad Manufacturing Agreement with CordenPharma - Contract Pharma
Cordenpharma, Viking Therapeutics form long-term partnership to provide key materials to make injectable and oral medications - Marketscreener.com
Finanzdaten der Viking Therapeutics Inc-Aktie (VKTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Viking Therapeutics Inc-Aktie (VKTX) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Mancini Marianna | Chief Operating Officer |
Jan 06 '25 |
Sale |
42.75 |
54,215 |
2,317,599 |
374,134 |
ZANTE GREG | Chief Financial Officer |
Jan 06 '25 |
Sale |
42.75 |
50,309 |
2,150,595 |
165,259 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):